

Philip Van Damme

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4315783/publications.pdf>

Version: 2024-02-01

313
papers

21,205
citations

7551

77
h-index

13727

129
g-index

333
all docs

333
docs citations

333
times ranked

21460
citing authors

#	ARTICLE	IF	CITATIONS
1	EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force. <i>European Journal of Neurology</i> , 2012, 19, 360-375.	1.7	860
2	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. <i>Neuron</i> , 2018, 97, 1268-1283.e6.	3.8	517
3	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. <i>Nature Genetics</i> , 2016, 48, 1043-1048.	9.4	494
4	Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 8157-8162.	3.3	472
5	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. <i>Lancet Neurology</i> , The, 2017, 16, 976-986.	4.9	472
6	Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. <i>Nature Neuroscience</i> , 2005, 8, 85-92.	7.1	464
7	Amyotrophic lateral sclerosis: a clinical review. <i>European Journal of Neurology</i> , 2020, 27, 1918-1929.	1.7	451
8	Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. <i>Neuron</i> , 2016, 90, 535-550.	3.8	437
9	Phase Separation of C9orf72 Dipeptide Repeats Perturbs Stress Granule Dynamics. <i>Molecular Cell</i> , 2017, 65, 1044-1055.e5.	4.5	437
10	HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. <i>Nature Medicine</i> , 2011, 17, 968-974.	15.2	405
11	The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2006, 1762, 1068-1082.	1.8	385
12	Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. <i>Journal of Cell Biology</i> , 2008, 181, 37-41.	2.3	376
13	Phase 1² Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS. <i>New England Journal of Medicine</i> , 2020, 383, 109-119.	13.9	354
14	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. <i>Lancet Neurology</i> , The, 2018, 17, 423-433.	4.9	342
15	HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. <i>Nature Communications</i> , 2017, 8, 861.	5.8	275
16	EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. <i>Nature Medicine</i> , 2012, 18, 1418-1422.	15.2	269
17	Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. <i>Scientific Reports</i> , 2016, 6, 20877.	1.6	239
18	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. <i>Nature Genetics</i> , 2021, 53, 1636-1648.	9.4	223

#	ARTICLE	IF	CITATIONS
19	NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. <i>Nature Genetics</i> , 2016, 48, 1037-1042.	9.4	218
20	Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. <i>Lancet Neurology</i> , The, 2010, 9, 986-994.	4.9	205
21	Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. <i>Brain</i> , 2013, 136, 471-482.	3.7	205
22	The C9ORF72 expansion mutation is a common cause of ALS+FTD in Europe and has a single founder. <i>European Journal of Human Genetics</i> , 2013, 21, 102-108.	1.4	201
23	Serum biomarker for progranulin-associated frontotemporal lobar degeneration. <i>Annals of Neurology</i> , 2009, 65, 603-609.	2.8	195
24	Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 14825-14830.	3.3	193
25	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2018, 17, 35-46.	4.9	193
26	Regional variation of Guillain-Barré syndrome. <i>Brain</i> , 2018, 141, 2866-2877.	3.7	190
27	Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. <i>Lancet Oncology</i> , The, 2010, 11, 1086-1095.	5.1	187
28	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	4.9	175
29	TDP-43 proteinopathies: a new wave of neurodegenerative diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 86-95.	0.9	174
30	Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. <i>Neurology</i> , 2017, 88, 2302-2309.	1.5	169
31	Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. <i>Neurology</i> , 2019, 92, e2661-e2673.	1.5	169
32	Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2011, 70, 964-973.	2.8	168
33	Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. <i>Muscle and Nerve</i> , 2019, 60, 14-24.	1.0	162
34	Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. <i>Lancet Neurology</i> , The, 2011, 10, 400-403.	4.9	156
35	Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. <i>Nature Communications</i> , 2014, 5, 4835.	5.8	156
36	Modelling amyotrophic lateral sclerosis: progress and possibilities. <i>DMM Disease Models and Mechanisms</i> , 2017, 10, 537-549.	1.2	156

#	ARTICLE	IF	CITATIONS
37	Expanded <i>ATXN2</i> CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. <i>Neurology</i> , 2011, 76, 2066-2072.	1.5	151
38	Loss of <i>TBK1</i> is a frequent cause of frontotemporal dementia in a Belgian cohort. <i>Neurology</i> , 2015, 85, 2116-2125.	1.5	151
39	<i>Progranulin</i> genetic variability contributes to amyotrophic lateral sclerosis. <i>Neurology</i> , 2008, 71, 253-259.	1.5	148
40	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. <i>Neurology</i> , 2018, 90, e22-e30.	1.5	148
41	A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 570-579.	0.9	138
42	Excitotoxicity and Amyotrophic Lateral Sclerosis. <i>Neurodegenerative Diseases</i> , 2005, 2, 147-159.	0.8	132
43	Project MinE: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. <i>European Journal of Human Genetics</i> , 2018, 26, 1537-1546.	1.4	129
44	Progranulin is Neurotrophic In Vivo and Protects against a Mutant TDP-43 Induced Axonopathy. <i>PLoS ONE</i> , 2010, 5, e13368.	1.1	127
45	GluR2-Dependent Properties of AMPA Receptors Determine the Selective Vulnerability of Motor Neurons to Excitotoxicity. <i>Journal of Neurophysiology</i> , 2002, 88, 1279-1287.	0.9	124
46	A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. <i>Human Molecular Genetics</i> , 2014, 23, 2220-2231.	1.4	123
47	Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. <i>Human Molecular Genetics</i> , 2013, 22, 1783-1790.	1.4	122
48	Novel Role for Vascular Endothelial Growth Factor (VEGF) Receptor-1 and Its Ligand VEGF-B in Motor Neuron Degeneration. <i>Journal of Neuroscience</i> , 2008, 28, 10451-10459.	1.7	119
49	Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2019, 85, 470-481.	2.8	118
50	The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. <i>Neuroscience Letters</i> , 2003, 343, 81-84.	1.0	115
51	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. <i>Cell</i> , 2018, 175, 1679-1687.e7.	13.5	115
52	Mutations in <i>SACS</i> cause atypical and late-onset forms of ARSACS. <i>Neurology</i> , 2010, 75, 1181-1188.	1.5	114
53	Genetic correlation between amyotrophic lateral sclerosis and schizophrenia. <i>Nature Communications</i> , 2017, 8, 14774.	5.8	114
54	Value of ¹⁸ F-Fluorodeoxyglucose-Positron-Emission Tomography in Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 553.	4.5	111

#	ARTICLE	IF	CITATIONS
55	Progranulin functions as a cathepsin D chaperone to stimulate axonal outgrowth in vivo. <i>Human Molecular Genetics</i> , 2017, 26, 2850-2863.	1.4	111
56	Inside out: the role of nucleocytoplasmic transport in ALS and FTL. <i>Acta Neuropathologica</i> , 2016, 132, 159-173.	3.9	109
57	UNC13A is a modifier of survival in amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2012, 33, 630.e3-630.e8.	1.5	107
58	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. <i>Autoimmunity Reviews</i> , 2016, 15, 983-993.	2.5	105
59	GluR2 Deficiency Accelerates Motor Neuron Degeneration in a Mouse Model of Amyotrophic Lateral Sclerosis. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2005, 64, 605-612.	0.9	104
60	A phase IIa trial of olesoxime in subjects with amyotrophic lateral sclerosis. <i>European Journal of Neurology</i> , 2014, 21, 529-536.	1.7	104
61	Loss-of-function mutations in HINT1 cause axonal neuropathy with neuromyotonia. <i>Nature Genetics</i> , 2012, 44, 1080-1083.	9.4	102
62	Diagnostic and Prognostic Performance of Neurofilaments in ALS. <i>Frontiers in Neurology</i> , 2018, 9, 1167.	1.1	100
63	Cellular Effects of Progranulin in Health and Disease. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 549-560.	1.1	98
64	A zebrafish model for C9orf72 ALS reveals RNA toxicity as a pathogenic mechanism. <i>Acta Neuropathologica</i> , 2018, 135, 427-443.	3.9	98
65	Amyloid precursor protein mutation E682K at the alternative β -secretase cleavage site increases $A\beta$ generation. <i>EMBO Molecular Medicine</i> , 2011, 3, 291-302.	3.3	97
66	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2014, 128, 397-410.	3.9	93
67	HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease. <i>Brain</i> , 2018, 141, 673-687.	3.7	93
68	IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients. <i>Journal of Autoimmunity</i> , 2017, 77, 104-115.	3.0	92
69	<i>C9orf72</i> and <i>UNC13A</i> are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: A genome-wide meta-analysis. <i>Annals of Neurology</i> , 2014, 76, 120-133.	2.8	91
70	International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 68-76.	1.4	89
71	Upregulation of HSP27 in a Transgenic Model of ALS. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2002, 61, 968-974.	0.9	87
72	Microbleeds and the Risk of Recurrent Stroke. <i>Stroke</i> , 2010, 41, 2005-2009.	1.0	87

#	ARTICLE	IF	CITATIONS
73	<i>TBK1</i> Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Human Mutation</i> , 2017, 38, 297-309.	1.1	87
74	Clinical features of <i>TBK1</i> carriers compared with <i>C9orf72</i> , <i>GRN</i> and non-mutation carriers in a Belgian cohort. <i>Brain</i> , 2016, 139, 452-467.	3.7	86
75	ATXN2 trinucleotide repeat length correlates with risk of ALS. <i>Neurobiology of Aging</i> , 2017, 51, 178.e1-178.e9.	1.5	86
76	Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 367-373.	0.9	86
77	Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: A prospective study. <i>Annals of Neurology</i> , 2011, 70, 79-83.	2.8	85
78	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2016, 17, 404-413.	1.1	84
79	Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 291-304.	1.8	82
80	The neurobiology of amyotrophic lateral sclerosis. <i>European Journal of Neuroscience</i> , 2010, 31, 2247-2265.	1.2	78
81	VEGF protects motor neurons against excitotoxicity by upregulation of GluR2. <i>Neurobiology of Aging</i> , 2010, 31, 2185-2191.	1.5	78
82	Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 cases. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 86.	1.2	77
83	Pathogenic cysteine mutations affect progranulin function and production of mature granulins. <i>Journal of Neurochemistry</i> , 2010, 112, 1305-1315.	2.1	76
84	Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: A systematic review using individual patient data. <i>Clinical Neurophysiology</i> , 2016, 127, 2684-2691.	0.7	74
85	Molecular Dissection of FUS Points at Synergistic Effect of Low-Complexity Domains in Toxicity. <i>Cell Reports</i> , 2018, 24, 529-537.e4.	2.9	74
86	Rotavirus vaccination in Europe: drivers and barriers. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 416-425.	4.6	72
87	Noninvasive Ventilation Improves Sleep in Amyotrophic Lateral Sclerosis: A Prospective Polysomnographic Study. <i>Journal of Clinical Sleep Medicine</i> , 2015, 11, 559-566.	1.4	72
88	Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1. <i>Neurobiology of Aging</i> , 2013, 34, 357.e7-357.e19.	1.5	69
89	Altered perivascular fibroblast activity precedes ALS disease onset. <i>Nature Medicine</i> , 2021, 27, 640-646.	15.2	69
90	Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease. <i>Neurotherapeutics</i> , 2017, 14, 417-428.	2.1	67

#	ARTICLE	IF	CITATIONS
91	Microglial Upregulation of Progranulin as a Marker of Motor Neuron Degeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 1191-1200.	0.9	64
92	The neurotrophic properties of progranulin depend on the granulin E domain but do not require sortilin binding. <i>Neurobiology of Aging</i> , 2013, 34, 2541-2547.	1.5	63
93	Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2014, 15, 344-350.	1.1	62
94	Restoration of Progranulin Expression Rescues Cortical Neuron Generation in an Induced Pluripotent Stem Cell Model of Frontotemporal Dementia. <i>Stem Cell Reports</i> , 2015, 4, 16-24.	2.3	62
95	Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2017, 16, 208-216.	4.9	62
96	Diagnostic Challenges and Clinical Characteristics of Hepatitis E Virus-Associated Guillain-Barré Syndrome. <i>JAMA Neurology</i> , 2017, 74, 26.	4.5	61
97	Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model. <i>Acta Neuropathologica Communications</i> , 2019, 7, 107.	2.4	61
98	Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients. <i>Neurobiology of Aging</i> , 2017, 51, 177.e9-177.e16.	1.5	60
99	Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study. <i>Neuromuscular Disorders</i> , 2019, 29, 167-186.	0.3	59
100	Rapamycin increases survival in ALS mice lacking mature lymphocytes. <i>Molecular Neurodegeneration</i> , 2013, 8, 31.	4.4	58
101	APP Processing in Human Pluripotent Stem Cell-Derived Neurons Is Resistant to NSAID-Based β -Secretase Modulation. <i>Stem Cell Reports</i> , 2013, 1, 491-498.	2.3	58
102	Association of a Locus in the <i>CAMTA1</i> Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2016, 73, 812.	4.5	57
103	Mutations in the Glycosyltransferase Domain of GLT8D1 Are Associated with Familial Amyotrophic Lateral Sclerosis. <i>Cell Reports</i> , 2019, 26, 2298-2306.e5.	2.9	57
104	<i>C9orf72</i> -derived arginine-containing dipeptide repeats associate with axonal transport machinery and impede microtubule-based motility. <i>Science Advances</i> , 2021, 7, .	4.7	57
105	Recent advances in motor neuron disease. <i>Current Opinion in Neurology</i> , 2009, 22, 486-492.	1.8	56
106	Prevention of intestinal obstruction reveals progressive neurodegeneration in mutant TDP-43 (A315T)mice. <i>Molecular Neurodegeneration</i> , 2014, 9, 24.	4.4	56
107	Clinical Evidence of Disease Anticipation in Families Segregating a <i>C9orf72</i> Repeat Expansion. <i>JAMA Neurology</i> , 2017, 74, 445.	4.5	56
108	Elongator subunit 3 (ELP3) modifies ALS through tRNA modification. <i>Human Molecular Genetics</i> , 2018, 27, 1276-1289.	1.4	56

#	ARTICLE	IF	CITATIONS
109	RNA Sequencing Analysis of Intracranial Aneurysm Walls Reveals Involvement of Lysosomes and Immunoglobulins in Rupture. <i>Stroke</i> , 2016, 47, 1286-1293.	1.0	55
110	Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. <i>Nature Genetics</i> , 2022, 54, 232-239.	9.4	55
111	G37R SOD1 mutant alters mitochondrial complex I activity, Ca ²⁺ uptake and ATP production. <i>Cell Calcium</i> , 2011, 49, 217-225.	1.1	54
112	Role of mitochondria in kainate-induced fast Ca ²⁺ transients in cultured spinal motor neurons. <i>Cell Calcium</i> , 2007, 42, 59-69.	1.1	53
113	Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth. <i>Neurobiology of Disease</i> , 2018, 111, 59-69.	2.1	52
114	C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. <i>Autophagy</i> , 2021, 17, 3306-3322.	4.3	52
115	An β -mercaptoacrylic acid derivative (PD150606) inhibits selective motor neuron death via inhibition of kainate-induced Ca ²⁺ influx and not via calpain inhibition. <i>Neuropharmacology</i> , 2002, 42, 706-713.	2.0	51
116	HDAC6 inhibition restores TDP ⁴³ pathology and axonal transport defects in human motor neurons with TARDBP mutations. <i>EMBO Journal</i> , 2021, 40, e106177.	3.5	51
117	Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis. <i>Neuron</i> , 2022, 110, 992-1008.e11.	3.8	51
118	TDP-43 M311V mutation in familial amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 354-355.	0.9	49
119	NIPA1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis. <i>Human Molecular Genetics</i> , 2012, 21, 2497-2502.	1.4	49
120	Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2384-2394.	1.7	49
121	Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. <i>Lancet Neurology</i> , The, 2018, 17, 689-698.	4.9	48
122	Detection of myositis-specific antibodies. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e7-e7.	0.5	48
123	Chloride Influx Aggravates Ca ²⁺ -Dependent AMPA Receptor-Mediated Motoneuron Death. <i>Journal of Neuroscience</i> , 2003, 23, 4942-4950.	1.7	47
124	Benefits of intensive insulin therapy on neuromuscular complications in routine daily critical care practice: a retrospective study. <i>Critical Care</i> , 2009, 13, R5.	2.5	47
125	C9orf72-generated poly-GR and poly-PR do not directly interfere with nucleocytoplasmic transport. <i>Scientific Reports</i> , 2019, 9, 15728.	1.6	47
126	Human motor units in microfluidic devices are impaired by FUS mutations and improved by HDAC6 inhibition. <i>Stem Cell Reports</i> , 2021, 16, 2213-2227.	2.3	47

#	ARTICLE	IF	CITATIONS
127	Ivermectin inhibits AMPA receptor-mediated excitotoxicity in cultured motor neurons and extends the life span of a transgenic mouse model of amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2007, 25, 8-16.	2.1	46
128	Association of Variants in the <i>SPTLC1</i> Gene With Juvenile Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 1236.	4.5	46
129	Use of Multimodal Imaging and Clinical Biomarkers in Presymptomatic Carriers of <i>C9orf72</i> Repeat Expansion. <i>JAMA Neurology</i> , 2020, 77, 1008.	4.5	45
130	Prospective Validation of ¹⁸ F-FDG Brain PET Discriminant Analysis Methods in the Diagnosis of Amyotrophic Lateral Sclerosis. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1238-1243.	2.8	44
131	Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2018-319586.	0.9	42
132	TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 604-607.	2.8	42
133	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. <i>JAMA Network Open</i> , 2021, 4, e2030194.	2.8	42
134	The occurrence of mutations in <i>FUS</i> in a Belgian cohort of patients with familial ALS. <i>European Journal of Neurology</i> , 2010, 17, 754-756.	1.7	41
135	Screening for lipoprotein receptor-related protein 4, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis. <i>Journal of Neurology</i> , 2017, 264, 1193-1203.	1.8	41
136	July 2017 ENCALS statement on edaravone. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 471-474.	1.1	41
137	Generation of a human induced pluripotent stem cell-based model for tauopathies combining three microtubule-associated protein TAU mutations which displays several phenotypes linked to neurodegeneration. <i>Alzheimer's and Dementia</i> , 2018, 14, 1261-1280.	0.4	41
138	Differentiation but not ALS mutations in FUS rewires motor neuron metabolism. <i>Nature Communications</i> , 2019, 10, 4147.	5.8	41
139	Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study. <i>Brain</i> , 2021, 144, 3392-3404.	3.7	39
140	Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases. <i>Muscle and Nerve</i> , 2006, 34, 391-405.	1.0	38
141	Frequency of C9orf72 repeat expansions in amyotrophic lateral sclerosis: a Belgian cohort study. <i>Neurobiology of Aging</i> , 2013, 34, 2890.e7-2890.e12.	1.5	38
142	Progranulin reduces insoluble TDP-43 levels, slows down axonal degeneration and prolongs survival in mutant TDP-43 mice. <i>Molecular Neurodegeneration</i> , 2018, 13, 55.	4.4	38
143	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. <i>Science Translational Medicine</i> , 2022, 14, eabj0264.	5.8	38
144	Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2019, 6, e590.	3.1	37

#	ARTICLE	IF	CITATIONS
145	Genetic Architecture of Adaptive Immune System Identifies Key Immune Regulators. <i>Cell Reports</i> , 2018, 25, 798-810.e6.	2.9	36
146	Astrocyte-derived Jagged-1 mitigates deleterious Notch signaling in amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2018, 119, 26-40.	2.1	35
147	Whole-genome sequencing reveals a coding non-pathogenic variant tagging a non-coding pathogenic hexanucleotide repeat expansion in C9orf72 as cause of amyotrophic lateral sclerosis. <i>Human Molecular Genetics</i> , 2012, 21, 2412-2419.	1.4	33
148	Exome sequencing reveals HINT1 mutations as a cause of distal hereditary motor neuropathy. <i>European Journal of Human Genetics</i> , 2014, 22, 847-850.	1.4	33
149	C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 281.1-281.	0.9	33
150	FUS-induced neurotoxicity in <i>Drosophila</i> is prevented by downregulating nucleocytoplasmic transport proteins. <i>Human Molecular Genetics</i> , 2018, 27, 4103-4116.	1.4	33
151	<i>ATXN1</i> repeat expansions confer risk for amyotrophic lateral sclerosis and contribute to TDP-43 mislocalization. <i>Brain Communications</i> , 2020, 2, fcaa064.	1.5	33
152	NEK1 genetic variability in a Belgian cohort of ALS and ALS-FTD patients. <i>Neurobiology of Aging</i> , 2018, 61, 255.e1-255.e7.	1.5	32
153	Unraveling the genetic landscape of autosomal recessive Charcot-Marie-Tooth neuropathies using a homozygosity mapping approach. <i>Neurogenetics</i> , 2015, 16, 33-42.	0.7	29
154	Serum neurofilament heavy chains as early marker of motor neuron degeneration. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1971-1979.	1.7	29
155	A phase III trial of <i>tirasemtiv</i> as a potential treatment for amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 584-594.	1.1	29
156	Tweaking Progranulin Expression: Therapeutic Avenues and Opportunities. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 713031.	1.4	28
157	Differential early subcortical involvement in genetic FTD within the GENFI cohort. <i>NeuroImage: Clinical</i> , 2021, 30, 102646.	1.4	28
158	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. <i>NeuroImage: Clinical</i> , 2019, 24, 102077.	1.4	27
159	Histone Deacetylase Inhibition Regulates Lipid Homeostasis in a Mouse Model of Amyotrophic Lateral Sclerosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11224.	1.8	27
160	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1805-1817.	3.7	27
161	Association of NIPA1 repeat expansions with amyotrophic lateral sclerosis in a large international cohort. <i>Neurobiology of Aging</i> , 2019, 74, 234.e9-234.e15.	1.5	26
162	Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 83.	1.2	26

#	ARTICLE	IF	CITATIONS
163	Structure of granzyme C reveals an unusual mechanism of protease autoinhibition. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5587-5592.	3.3	25
164	Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 436-437.	0.9	25
165	Myasthenia gravis with muscle specific kinase antibodies mimicking amyotrophic lateral sclerosis. Neuromuscular Disorders, 2016, 26, 350-353.	0.3	24
166	Targeted Genetic Screen in Amyotrophic Lateral Sclerosis Reveals Novel Genetic Variants with Synergistic Effect on Clinical Phenotype. Frontiers in Molecular Neuroscience, 2017, 10, 370.	1.4	24
167	Motor cortex metabolite alterations in amyotrophic lateral sclerosis assessed in vivo using edited and non-edited magnetic resonance spectroscopy. Brain Research, 2019, 1718, 22-31.	1.1	24
168	Rare Variant Burden Analysis within Enhancers Identifies CAV1 as an ALS Risk Gene. Cell Reports, 2020, 33, 108456.	2.9	24
169	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.4	24
170	The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD. Molecular Neurodegeneration, 2022, 17, 22.	4.4	24
171	No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis. Human Molecular Genetics, 2014, 23, 1916-1922.	1.4	23
172	Identification and characterization of Nanobodies targeting the EphA4 receptor. Journal of Biological Chemistry, 2017, 292, 11452-11465.	1.6	23
173	A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations. European Neurology, 2019, 81, 223-230.	0.6	23
174	A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A. Orphanet Journal of Rare Diseases, 2021, 16, 433.	1.2	23
175	Structural variation analysis of 6,500 whole genome sequences in amyotrophic lateral sclerosis. Npj Genomic Medicine, 2022, 7, 8.	1.7	23
176	Clinical implications of recent breakthroughs in amyotrophic lateral sclerosis. Current Opinion in Neurology, 2013, 26, 466-472.	1.8	22
177	Reconsidering the causality of TIA1 mutations in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 1-3.	1.1	22
178	Circadian sleep/wake-associated cells show dipeptide repeat protein aggregates in C9orf72-related ALS and FTLD cases. Acta Neuropathologica Communications, 2019, 7, 189.	2.4	22
179	RNA-Sequencing Highlights Inflammation and Impaired Integrity of the Vascular Wall in Brain Arteriovenous Malformations. Stroke, 2020, 51, 268-274.	1.0	22
180	Moving Toward Multicenter Therapeutic Trials in Amyotrophic Lateral Sclerosis: Feasibility of Data Pooling Using Different Translocator Protein PET Radioligands. Journal of Nuclear Medicine, 2020, 61, 1621-1627.	2.8	22

#	ARTICLE	IF	CITATIONS
181	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum τ and pNfH: A Longitudinal Multicentre Study. <i>Annals of Neurology</i> , 2022, 91, 33-47.	2.8	21
182	The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis. <i>Brain</i> , 2022, 145, 1207-1210.	3.7	21
183	Non-invasive ventilation in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2013, 14, 85-95.	1.1	20
184	Beta-2 microglobulin is important for disease progression in a murine model for amyotrophic lateral sclerosis. <i>Frontiers in Cellular Neuroscience</i> , 2013, 7, 249.	1.8	20
185	Randomized crossover trial of ventilator modes during noninvasive ventilation titration in amyotrophic lateral sclerosis. <i>Respirology</i> , 2017, 22, 1212-1218.	1.3	20
186	Microglia lacking a peroxisomal β -oxidation enzyme chronically alter their inflammatory profile without evoking neuronal and behavioral deficits. <i>Journal of Neuroinflammation</i> , 2019, 16, 61.	3.1	20
187	TRICALS: creating a highway toward a cure. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 496-501.	1.1	20
188	FUS (fused in sarcoma) is a component of the cellular response to topoisomerase α -induced DNA breakage and transcriptional stress. <i>Life Science Alliance</i> , 2019, 2, e201800222.	1.3	20
189	H63D polymorphism in HFE is not associated with amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2013, 34, 1517.e5-1517.e7.	1.5	19
190	Granzyme M targets topoisomerase II α to trigger cell cycle arrest and caspase-dependent apoptosis. <i>Cell Death and Differentiation</i> , 2014, 21, 416-426.	5.0	19
191	Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR). <i>Acta Neurologica Belgica</i> , 2015, 115, 97-104.	0.5	19
192	Genetic ablation of IP3receptor 2 increases cytokines and decreases survival of SOD1 ^{G93A} mice. <i>Human Molecular Genetics</i> , 2016, 25, 3491-3499.	1.4	19
193	Multicenter validation of [¹⁸ F]-FDG PET and support-vector machine discriminant analysis in automatically classifying patients with amyotrophic lateral sclerosis versus controls. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 570-577.	1.1	19
194	Innovating Clinical Trials for Amyotrophic Lateral Sclerosis. <i>Neurology</i> , 2021, 97, 528-536.	1.5	19
195	Tau levels do not influence human ALS or motor neuron degeneration in the SOD1 ^{G93A} mouse. <i>Neurology</i> , 2010, 74, 1687-1693.	1.5	18
196	Dantrolene is neuroprotective in vitro, but does not affect survival in SOD1 ^{G93A} mice. <i>Neuroscience</i> , 2012, 220, 26-31.	1.1	18
197	Genetic ablation of phospholipase C delta 1 increases survival in SOD1 ^{G93A} mice. <i>Neurobiology of Disease</i> , 2013, 60, 11-17.	2.1	18
198	Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. <i>Journal of the Neurological Sciences</i> , 2019, 407, 116419.	0.3	18

#	ARTICLE	IF	CITATIONS
199	Dystrophin deficiency leads to dysfunctional glutamate clearance in iPSC derived astrocytes. <i>Translational Psychiatry</i> , 2019, 9, 200.	2.4	18
200	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Applied Neuropsychology Adult</i> , 2022, 29, 112-119.	0.7	18
201	Liquidâ€“Liquid Phase Separation Enhances TDP-43 LCD Aggregation but Delays Seeded Aggregation. <i>Biomolecules</i> , 2021, 11, 548.	1.8	18
202	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 48-55.	1.4	17
203	Clinical spectrum of the anti-GQ1b antibody syndrome: a case series of eight patients. <i>Acta Neurologica Belgica</i> , 2019, 119, 29-36.	0.5	17
204	EphA4 loss improves social memory performance and alters dendritic spine morphology without changes in amyloid pathology in a mouse model of Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 102.	3.0	17
205	Derivation of norms for the Dutch version of the Edinburgh cognitive and behavioral ALS screen. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 19-27.	1.1	17
206	Myositis as a neuromuscular complication of immune checkpoint inhibitors. <i>Acta Neurologica Belgica</i> , 2020, 120, 355-364.	0.5	17
207	Analysis of the KIFAP3 gene in amyotrophic lateral sclerosis: a multicenter survival study. <i>Neurobiology of Aging</i> , 2014, 35, 2420.e13-2420.e14.	1.5	16
208	How robust is ACTIVLIM for the follow-up of activity limitations in patients with neuromuscular diseases?. <i>Neuromuscular Disorders</i> , 2016, 26, 211-220.	0.3	16
209	Conditional deletion of <i>Id2</i> or <i>Notch1</i> in oligodendrocyte progenitor cells does not ameliorate disease outcome in <i>SOD1G93A</i> mice. <i>Neurobiology of Aging</i> , 2018, 68, 1-4.	1.5	16
210	Exome array analysis of rare and low frequency variants in amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2019, 9, 5931.	1.6	16
211	Consistent improvement with eculizumab across muscle groups in myasthenia gravis. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1327-1339.	1.7	16
212	Intracerebroventricular delivery of vascular endothelial growth factor in patients with amyotrophic lateral sclerosis, a phase I study. <i>Brain Communications</i> , 2020, 2, fcaa160.	1.5	16
213	Whole-genome sequencing reveals that variants in the Interleukin 18 Receptor Accessory Protein 3â€™UTR protect against ALS. <i>Nature Neuroscience</i> , 2022, 25, 433-445.	7.1	16
214	Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease. <i>Neurology</i> , 2022, 99, .	1.5	16
215	Na ⁺ Entry Through AMPA Receptors Results in Voltage-Gated K ⁺ Channel Blockade in Cultured Rat Spinal Cord Motoneurons. <i>Journal of Neurophysiology</i> , 2002, 88, 965-972.	0.9	15
216	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. <i>Neurobiology of Aging</i> , 2018, 69, 293.e9-293.e11.	1.5	15

#	ARTICLE	IF	CITATIONS
217	Placebo effect in chronic inflammatory demyelinating polyneuropathy: The <sc>PATH</sc> study and a systematic review. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 230-237.	1.4	15
218	A multi-center study of neurofilament assay reliability and inter-laboratory variability. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 452-458.	1.1	15
219	Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2681-2690.	3.3	15
220	Necrosomeâ€positive granulovacuolar degeneration is associated with TDPâ€43 pathological lesions in the hippocampus of ALS/FTLD cases. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 328-345.	1.8	15
221	A mapping review of international guidance on the management and care of amyotrophic lateral sclerosis (ALS). <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2016, 17, 325-336.	1.1	14
222	Finger extension weakness and downbeat nystagmus motor neuron disease syndrome: A novel motor neuron disorder?. <i>Muscle and Nerve</i> , 2017, 56, 1164-1168.	1.0	14
223	Non-invasive assessment of disease progression and neuroprotective effects of dietary coconut oil supplementation in the ALS SOD1G93A mouse model: A 1H-magnetic resonance spectroscopic study. <i>NeuroImage: Clinical</i> , 2018, 20, 1092-1105.	1.4	14
224	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 276-286.	1.1	14
225	<i>SCFD1</i> expression quantitative trait loci in amyotrophic lateral sclerosis are differentially expressed. <i>Brain Communications</i> , 2021, 3, fcab236.	1.5	14
226	Autosomal recessive spastic ataxia of Charlevoix-Saguenay. <i>Neurology</i> , 2009, 72, 1790-1790.	1.5	13
227	Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS) Syndrome Mimicking Herpes Simplex Encephalitis on Imaging Studies. <i>Journal of Computer Assisted Tomography</i> , 2013, 37, 279-281.	0.5	13
228	Metabolic Syndrome, Neurotoxic 1-Deoxysphingolipids and Nervous Tissue Inflammation in Chronic Idiopathic Axonal Polyneuropathy (CIAP). <i>PLoS ONE</i> , 2017, 12, e0170583.	1.1	13
229	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the preâ€randomization phase of the Polyneuropathy And Treatment with Hizentra study. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 72-79.	1.4	13
230	Neuronal overexpression of IP3 receptor 2 is detrimental in mutant SOD1 mice. <i>Biochemical and Biophysical Research Communications</i> , 2012, 429, 210-213.	1.0	12
231	Developments in treatments for amyotrophic lateral sclerosis via intracerebroventricular or intrathecal delivery. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 955-963.	1.9	12
232	In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	12
233	An ALS case with 38 (G4C2)-repeats in the C9orf72 gene shows TDP-43 and sparse dipeptide repeat protein pathology. <i>Acta Neuropathologica</i> , 2019, 137, 855-858.	3.9	12
234	AAV9-mediated gene delivery of MCT1 to oligodendrocytes does not provide a therapeutic benefit in a mouse model of ALS. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 508-519.	1.8	12

#	ARTICLE	IF	CITATIONS
235	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 127.	3.0	12
236	Insights into the identification of a molecular signature for amyotrophic lateral sclerosis exploiting integrated microRNA profiling of iPSC-derived motor neurons and exosomes. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 189.	2.4	12
237	Progranulin does not affect motor neuron degeneration in mutant SOD1 mice and rats. <i>Neurobiology of Aging</i> , 2013, 34, 2302-2303.	1.5	11
238	Prognostic value of clinical and electrodiagnostic parameters at time of diagnosis in patients with amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 341-350.	1.1	11
239	From lexical regularities to axiomatic patterns for the quality assurance of biomedical terminologies and ontologies. <i>Journal of Biomedical Informatics</i> , 2018, 84, 59-74.	2.5	11
240	Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis. <i>Acta Neuropathologica Communications</i> , 2019, 7, 114.	2.4	11
241	Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of <sc>REGAIN</sc> and its extension study. <i>Muscle and Nerve</i> , 2021, 64, 662-669.	1.0	11
242	Semantic modelling of common data elements for rare disease registries, and a prototype workflow for their deployment over registry data. <i>Journal of Biomedical Semantics</i> , 2022, 13, 9.	0.9	11
243	140th Annual Meeting American Neurological Association. <i>Annals of Neurology</i> , 2015, 78, S1-S242.	2.8	10
244	Patient-ventilator asynchrony, leaks and sleep in patients with amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2016, 17, 343-350.	1.1	10
245	Reducing EphA4 before disease onset does not affect survival in a mouse model of Amyotrophic Lateral Sclerosis. <i>Scientific Reports</i> , 2019, 9, 14112.	1.6	10
246	Brain metabolic changes across Kingâ€™s stages in amyotrophic lateral sclerosis: a 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1124-1133.	3.3	10
247	The Effect of <sc><i>SMN</i></sc> Gene Dosage on <sc>ALS</sc> Risk and Disease Severity. <i>Annals of Neurology</i> , 2021, 89, 686-697.	2.8	10
248	Characterising ALS disease progression according to El Escorial and Gold Coast criteria. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 865-870.	0.9	10
249	Acute ataxic neuropathy associated with hepatitis E virus infection. <i>Muscle and Nerve</i> , 2015, 52, 464-465.	1.0	9
250	Non-invasive characterization of amyotrophic lateral sclerosis in a hTDP-43A315T mouse model: A PET-MR study. <i>NeuroImage: Clinical</i> , 2020, 27, 102327.	1.4	9
251	Diagnostic yield of testing for <i>RFC1</i> repeat expansions in patients with unexplained adult-onset cerebellar ataxia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1233-1234.	0.9	9
252	Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 821-831.	4.9	9

#	ARTICLE	IF	CITATIONS
253	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. <i>Molecular Neurodegeneration</i> , 2021, 16, 79.	4.4	9
254	Neuromuscular complications after COVID-19 vaccination: a series of eight patients. <i>Acta Neurologica Belgica</i> , 2022, 122, 753-761.	0.5	9
255	Polymorphisms in the GluR2 gene are not associated with amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2012, 33, 418-420.	1.5	8
256	Dipeptide repeat protein and TDP-43 pathology along the hypothalamic-pituitary axis in C9orf72 and non-C9orf72 ALS and FTLD-TDP cases. <i>Acta Neuropathologica</i> , 2020, 140, 777-781.	3.9	8
257	Detection of multiple myositis-specific autoantibodies in unique patients with idiopathic inflammatory myopathy: A single centre-experience and literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 486-494.	1.6	8
258	Investigating the Endo-Lysosomal System in Major Neurocognitive Disorders Due to Alzheimer's Disease, Frontotemporal Lobar Degeneration and Lewy Body Disease: Evidence for SORL1 as a Cross-Disease Gene. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13633.	1.8	8
259	Long-lasting changes in GABA responsiveness in cultured neurons. <i>Neuroscience Letters</i> , 2004, 365, 69-72.	1.0	7
260	FDG-PET findings in three cases of Mills syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 87, jnnp-2014-309952.	0.9	7
261	Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 533-547.	3.3	7
262	Glucose metabolic brain patterns to discriminate amyotrophic lateral sclerosis from Parkinson plus syndromes. <i>EJNMMI Research</i> , 2018, 8, 110.	1.1	7
263	Prognostic value of neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. <i>Brain Communications</i> , 2021, 3, fcab018.	1.5	7
264	Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. <i>Clinical Neurophysiology</i> , 2022, 138, 231-240.	0.7	7
265	Prognostic relationship of neurofilaments, CHIT1, YKL-40 and MCP-1 in amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 681-682.	0.9	7
266	HDAC3 Inhibition Stimulates Myelination in a CMT1A Mouse Model. <i>Molecular Neurobiology</i> , 2022, 59, 3414-3430.	1.9	7
267	The neonatal sarcoplasmic reticulum Ca ²⁺ -ATPase gives a clue to development and pathology in human muscles. <i>Journal of Muscle Research and Cell Motility</i> , 2015, 36, 195-203.	0.9	6
268	Defining Y-SNP variation among the Flemish population (Western Europe) by full genome sequencing. <i>Forensic Science International: Genetics</i> , 2017, 31, e12-e16.	1.6	6
269	How much of the missing heritability of ALS is hidden in known ALS genes?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 794-794.	0.9	6
270	PCYT2 mutations disrupting etherlipid biosynthesis: phenotypes converging on the CDP-ethanolamine pathway. <i>Brain</i> , 2021, 144, e17-e17.	3.7	6

#	ARTICLE	IF	CITATIONS
271	STING-Induced Inflammation " A Novel Therapeutic Target in ALS?. New England Journal of Medicine, 2021, 384, 765-767.	13.9	6
272	Is there a glucose metabolic signature of spreading TDP-43 pathology in amyotrophic lateral sclerosis?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 96-104.	0.4	6
273	Genetic Creutzfeldt-Jakob disease mimicking chronic inflammatory demyelinating polyneuropathy. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e173.	3.1	5
274	Frontotemporal Lobar Degeneration Case with an N-Terminal TUBA4A Mutation Exhibits Reduced TUBA4A Levels in the Brain and TDP-43 Pathology. Biomolecules, 2022, 12, 440.	1.8	5
275	Cellular Stress Induces Nucleocytoplasmic Transport Deficits Independent of Stress Granules. Biomedicines, 2022, 10, 1057.	1.4	5
276	Generation of Human Motor Units with Functional Neuromuscular Junctions in Microfluidic Devices. Journal of Visualized Experiments, 2021, , .	0.2	4
277	Genome-Wide Analyses Identify KIF5A as a Novel ALS Gene. SSRN Electronic Journal, 0, , .	0.4	4
278	A 62-Year-Old Woman with Muscle Weakness. Clinical Chemistry, 2015, 61, 1133-1135.	1.5	3
279	Topographical Guidance of PSC-Derived Cortical Neurons. Journal of Nanomaterials, 2018, 2018, 1-10.	1.5	3
280	Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 481-488.	1.1	3
281	G.P.3. Neuromuscular Disorders, 2014, 24, 795.	0.3	2
282	PET Imaging in ALS. , 0, , .		2
283	Anterior interosseous mononeuropathy associated with HEV infection. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e429.	3.1	2
284	Lowering EphA4 Does Not Ameliorate Disease in a Mouse Model for Severe Spinal Muscular Atrophy. Frontiers in Neuroscience, 2019, 13, 1233.	1.4	2
285	RNF170 mutation causes autosomal dominant sensory ataxia with variable pyramidal involvement. European Journal of Neurology, 2022, 29, 345-349.	1.7	2
286	Correlations between measures of ALS respiratory function: is there an alternative to FVC?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 495-504.	1.1	2
287	Quantitative Nucleocytoplasmic Transport Assays in Cellular Models of Neurodegeneration. Bio-protocol, 2020, 10, e3659.	0.2	2
288	Respiratory onset of amyotrophic lateral sclerosis in a pregnant woman with a novel <i>SOD1</i> mutation. European Journal of Neurology, 2022, 29, 1279-1283.	1.7	2

#	ARTICLE	IF	CITATIONS
289	Chapter 10 Excitotoxicity and Oxidative Stress in Pathogenesis of Amyotrophic Lateral Sclerosis/Motor Neuron Disease. Blue Books of Practical Neurology, 2003, 28, 259-cp1.	0.1	1
290	An unusual presentation of Guillain-Barre syndrome associated with monospecific anti-GD1b antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 587-588.	0.9	1
291	Peripheral progranulin levels do not reflect brain progranulin levels. Future Neurology, 2014, 9, 521-524.	0.9	1
292	Negative commercial screening test for paraneoplastic antibodies in a case of opsoclonus. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e329.	3.1	1
293	Another piece in the progranulin puzzle: special binding between progranulin and prosaposin creates additional lysosomal access. Journal of Neurochemistry, 2017, 143, 154-157.	2.1	1
294	Analytical performance of a CE-marked immunoassay to quantify phosphorylated neurofilament heavy chains. Clinical Chemistry and Laboratory Medicine, 2019, 57, e199-e202.	1.4	1
295	Distinguishing Primary Lateral Sclerosis from Parkinsonian Syndromes with the Help of Advanced Imaging. Journal of Nuclear Medicine, 2021, 62, 1318-1319.	2.8	1
296	Neuropathy of the phrenic nerve associated with antiganglioside antibodies. European Journal of Neurology, 2021, 28, 2138-2141.	1.7	1
297	Psychopathology in premanifest C9orf72 repeat expansion carriers. Journal of Neurology, Neurosurgery and Psychiatry, 2021, , jnnp-2021-327774.	0.9	1
298	FAIRification Efforts of Clinical Researchers: The Current State of Affairs. Studies in Health Technology and Informatics, 2021, 287, 35-39.	0.2	1
299	The role of AMPA receptors and VEGF in ALS. Verhandelingen - Koninklijke Academie Voor Geneeskunde Van België, 2009, 71, 241-50.	0.2	1
300	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	1.5	1
301	From El Escorial to Awaji: where do we go next with the amyotrophic lateral sclerosis criteria?. Neurodegenerative Disease Management, 2012, 2, 135-140.	1.2	0
302	G.P.253. Neuromuscular Disorders, 2014, 24, 893.	0.3	0
303	T.P.39. Neuromuscular Disorders, 2014, 24, 905-906.	0.3	0
304	Cost of Illness Study In Patients With Myasthenia Gravis Treated With Plasma Exchange Therapy In Belgium. Value in Health, 2016, 19, A592.	0.1	0
305	Database crossing allows better understanding of neuromuscular disorders epidemiology: The Belgian example. Neuromuscular Disorders, 2016, 26, S207.	0.3	0
306	Possible influence of <sc>AMPD</sc>1 on cholinergic neurotransmission and sleep. Journal of Sleep Research, 2016, 25, 124-126.	1.7	0

#	ARTICLE	IF	CITATIONS
307	Intravenous versus subcutaneous immunoglobulin â€œ Authors' reply. Lancet Neurology, The, 2018, 17, 393-394.	4.9	0
308	REGISTRIES AND CARE OF NEUROMUSCULAR DISORDERS. Neuromuscular Disorders, 2018, 28, S117.	0.3	0
309	P.69NEO1 and NEO-EXT studies: exploratory efficacy of repeat avalglucosidase alfa dosing for up to 5 years in participants with late-onset Pompe disease (LOPD). Neuromuscular Disorders, 2019, 29, S60-S61.	0.3	0
310	NEO1 and NEO-EXT studies: Long-term safety of repeat avalglucosidase alfa dosing for 4.5 years in late-onset Pompe disease patients. Molecular Genetics and Metabolism, 2019, 126, S115-S116.	0.5	0
311	AB0696â€¦DETECTION OF COEXISTING MYOSITIS-SPECIFIC AUTOANTIBODIES WITH LINE AND DOT IMMUNOASSAYS IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. , 2019, , .		0
312	Papillary thyroid carcinoma presenting with severe Guillain-BarrÃ© syndrome. Acta Clinica Belgica, 2021, 76, 236-238.	0.5	0
313	Knowledge, attitudes and behaviours towards vaccination: a survey of university students in Europe. European Journal of Public Health, 2020, 30, .	0.1	0